Quarterly Result26 May 2025, 07:52 pm
Aurobindo Pharma Reports 10.6% YoY Revenue Growth in Q4FY25, Net Profit at INR 903 Cr
AI Summary
Aurobindo Pharma Limited announced its consolidated financial results for the quarter ended March 31, 2025. The company reported a 10.6% YoY increase in revenue from operations, which stood at INR 8,382 Cr. The US formulations revenue increased by 13.5% YoY to INR 4,072 Cr, and Europe formulations revenue increased by 17.2% YoY to INR 2,147 Cr. Growth Markets revenue decreased by 7.8% YoY to INR 786 Cr. Net profit for the period stood at INR 903 Cr. The company received final approval for 5 ANDAs from the USFDA.
Key Highlights
- Revenue from operations increased by 10.6% YoY to INR 8,382 Cr
- US formulations revenue increased by 13.5% YoY to INR 4,072 Cr
- Europe formulations revenue increased by 17.2% YoY to INR 2,147 Cr
- Net profit for the period stood at INR 903 Cr
- Received final approval for 5 ANDAs from the USFDA